Recent Study by Dr. Konstandinos A Plestis, Chief of Cardiothoracic and Vascular Surgery, Thomas Jefferson University
Minimally Invasive Aortic Surgery With Emphasis On Technical Aspects, Extracorporeal Circulation Management And Cardioplegic Technique
John Fung, MD, PhD, a pioneer transplant surgeon and newly named Director of the Cleveland Clinic Health System Center for Transplantation recently received the 2015 Thomas E. Starzl Prize in Surgery and Immunology in May.
The Thomas E. Starzl Transplantation Institute and Department of Surgery at the University of Pittsburgh Medical Center (UPMC) award the prize annually to an international leader in organ transplantation. Read More…
Dr John Fung recently presented on Organ Preservation Solutions at the ESOT congress. Below is his presentation is two parts.
Saitoh (2000) – Heart preservation in HTK solution: role of coronary vasculature in recovery of cardiac function
Poor myocardial tolerance to prolonged cold ischemia remains a major concern in heart transplantation. In this study, we estimated superiority of Histidine-Tryptophan-Ketoglutarate (HTK) over University of Wisconsin (UW) as a cardiac preservation solution.
Increasing allograft ischemic time is a significant risk factor for mortality following heart transplantation (HTx). The purpose of this study was to evaluate the protective effects of histidinetryptophan-ketoglutarate (HTK) and Celsior (CEL) using a rat HTx model with prolonged cold storage.
This study compared the experimental outcomes of donor heart preservation in rats between Custodiol HTK and UW solutions. It concluded that HTK is much more effective than UW solution for heart preservation, and that HTK may lead to better techniques in heart preservation for transplantation.
This study compares the efficacy of myocardial protection in a single dose of Custodiol HTK with repeated doses of cold blood cardioplegia. This study concluded that a single dose of Bretschneider’s HTK solution could effectively reduce pumping time and afford similar myocardial protection compared with repeated doses of CBC in the preservation of donated hearts.
This study compares Celsior and Custodiol preservation solutions in canine hearts in regards to the postichemic recovery of the organs. It found that there was no advantage of cardioplegia with Celsior over cardioplegia with Custodiol.
Schoening (2015) – Warm HTK donor pretreatment reduces liver injury during static cold storage in experimental rat liver transplantation
The new concept of warm HTK pretreatment significantly reduced ischemia-reperfusion injury. The reduced ischemia-reperfusion injury was due to MMP inhibition. Warm HTK donor pretreatment is easy to handle and could further improve HTK’s potency in liver preservation.
With the advent of segmental liver allografts from liver donors, reduced-size cadaveric allografts, and split cadaveric allografts, pediatric pre-transplantation patient mortality has reduced. However, this expansion of the donor pool for size-appropriate allografts for patients with end-stage liver disease has led to an increased incidence of biliary complications.
There is a lack of universally accepted clinical parameters to guide the utilization of donation after cardiac death (DCD) donor livers and it is unclear as to which patients would benefit most from these organs.
Alexis Carrel took the initial steps in the area of organ preservation by successfully preserving an artery for several days using chilled Locke’s solution, although this effort was largely overshadowed by his work in vascular surgery and organ transplantation.
This large retrospective study showed that there is a significantly increased risk of ischemic-type biliary lesions when using UW compared to HTK. From this single center study they concluded that they would exclusively use HTK in liver transplantation.
This single center study comparing HTK to UW in liver transplantation found that there is the potential for HTK to protect against biliary complications in comparison to UW. They concluded that given the lower cost per donor of HTK it may be the preferable solution for general use.
This single center retrospective study analyzed the effects of the donors, recipients, as well as the technical factors involved in liver transplantation and their effect on biliary complications. They found that the most important variables to reduce biliary complications are decreased warm ischemic times, use of HTK, and the use of a stent.
Fridell (2010) – Histidine-tryptophan-ketoglutarate for pancreas allograft preservation: the Indiana University experience
Histidine-tryptophan-ketoglutarate solution (HTK) has been scrutinized for use in pancreas transplantation.
This study compares the efficacy of HTK and UW in preservation of pancreas grafts in regards to patient and graft survival as well as some of the biomarkers of successful transplantation. They found that HTK is clinically comparable to UW, and that both solutions are safe for pancreas preservation.
This study compared the ability of HTK and UW to preserve pancreas grafts for islet transplantation. They found equivalent results between HTK and UW for preservation of pancreata.
This study found that in the clinical setting with cold ischemic times averaging 10 hours, HTK and UW solutions appear to be equivalent in preserving pancreata for transplantation.
This abstract presented at the American Transplant Congress in 2009, found that at their center there was no difference in pancreas transplant outcomes or biomarkers between HTK and UW preservation solutions with cold ischemic times up to 15 hours.
Klaus (2007) – Kidney transplantation with Belzer or Custodiol solution: a randomized prospective study
The purpose of this study was to compare the Belzer vs Custodiol solutions for cadaveric kidney perfusion in relation to delayed graft function, renal function, acute rejection episodes, and patient and graft survivals.
This study compares Custodiol HTK and UW preservation solutions in kidney allografts with prolonged cold ischemic times greater than 16 hours. They found that HTK is at least comparable to UW in the preservation of kidney allografts even with prolonged cold ischemic times. Even with ischemic times longer than 24 hours HTK was not inferior to UW in organ preservation.
This study compared HTK, UW and Euro-Collins solution in the preservation of kidney grafts with regards to the initial graft function as well as the long term graft survival. The study concluded that both HTK and UW were superior in comparison to EC solution, and that HTK is comparable to UW in preserving kidneys from heart beating donors.
This large retrospective single center comparison between HTK and UW transplant solutions in kidney transplantation compares multiple factors including patient and graft survival as well as delayed graft function. It concludes that although there was increased incidence of DGF with HTK, there was similar efficacy between HTK and UW in terms of patient and graft survival.
This abstract presented at the ATC in 2012 retrospectively reviewed living donor kidney transplants comparing HTK and UW to LR solutions. They found that HTK was superior to LR in preventing DGF, and that both HTK and UW are more cost effective than LR in live donor kidney transplantation.
Latchana (2015) – Preservation solutions used during abdominal transplantation: Current status and outcomes
Evolution of transplantation and graft preservation are discussed followed by classification of preservation solutions according to the composition of electrolytes, impermeants, buffers, antioxidants, and energy precursors.
Studies, Posters and Abstracts
- Biliary Reconstruction in Pediatric Liver Transplantation
- Severe Hypernatremia in Deceased Liver Donors
- Post Liver Transplant Biliary Complications
- Best Practices Pediatric Liver Transplant Programs
- Single Center Outcomes for Donation
- Comparison of Solutions in Extended Criteria Liver Donors
Clearly Custodiol Blog
- Plegisol is on backorder (shortage)
- Dr. John Fung's Power Point Presentation on Organ Preservation Solutions
- Transplantation of a horseshoe kidney from a living donor: Case report, long term outcome and donor safety
- Exhibiting at Kidney and Pancreas Transplant Meeting Oct. 3rd
- Robert O'Flynn joins Essential Pharmaceuticals for Custodiol HTK